SEC Form 4 · accession 0001114220-18-000016
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Greg Madison
Officer — President and CEO · Director
Period of report
Nov 7, 2017
Accepted (ET)
Jan 31, 2018 · 5:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 7, 2017 | A | 125,000 | $0.00 | A | 492,620 | D | |
| Common StockF2 | Nov 7, 2017 | F | 58,813 | $5.15 | D | 433,807 | D | |
| Common StockF3,F4 | Jan 29, 2018 | A | 4,403 | $4.81 | D | 429,404 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The 125,000 shares are shares of common stock that were delivered to the reporting person upon the achievement of a performance condition associated with a portion of a restricted stock award that was granted on April 30, 2015.
- F2A total of 58,813 shares of common stock were surrendered by Mr. Madison and returned to the company in order to satisfy Mr. Madison's income tax withholding obligation upon the vesting of the 125,000 shares of restricted stock on November 6, 2017.
- F3Sale of a total of 4,403 shares of common stock was made in order to satisfy Mr. Madison's income tax withholding obligation upon the vesting of 12,812 shares of restricted stock on January 26, 2018. Mr. Madison had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
- F4Includes 201,248 shares of restricted stock.